Litcius/Paper detail

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

Antonio Uccelli, Alice Laroni, Rehiana Ali, Mario Alberto Battaglia, Morten Blinkenberg, Lou Brundin, Michel Clanet, Óscar Fernández, James Marriott, Paolo A. Muraro, Seyed Massood Nabavi, Roberto S Oliveri, Ernst W. Radue, Cristina Ramo‐Tello, Irene Schiavetti, Johann Sellner, Per Soelberg Sørensen, Maria Pia Sormani, Jens Wuerfel, Mark S. Freedman, Naser Aghdami, Eduardo Agüera, Rehiana Ali, David Allan, Leila Arab, Mario Alberto Battaglia, I. Berry, Morten Blinkenberg, Bruno Bonetti, Lou Brundin, Chiara Capelli, Lucio Castellan, Maria Cellerino, Maria Teresa Cencioni, Michel Clanet, Gıancarlo Comı, David W. Courtman, Francesco Dazzi, Anne Fischer‐Nielsen, Óscar Fernández, Victoria Fernández, Mark S. Freedman, Roberto Furlan, Mario Gimona, Francesca Gualandi, Qingdong Guan, Ellen Iacobaeus, Matilde Inglese, Martino Introna, Guillermo Izquierdo, Shahedeh Karimi, Alice Laroni, Katarina Le Blanc, Sandra Loaiza, Shahrukh Mallik, Stephen B. Marley, Ruth Ann Marrie, James Marriot, Gianvito Martino, Seyed Massood Nabavi, David Miller, Paolo A. Muraro, Richard Nicholas, Roberto S Oliveri, Giovanni Orengo, Renuka Palanicawande, Matteo Pardini, Ernst W. Radue, Cristina Ramo‐Tello, Carolina Rush, Irene Schiavetti, Johann Sellner, Luc Sensebé, Per Soelberg Sørensen, Maria Pia Sormani, Dirk Strunk, David Szwajcer, Claire Thalamas, Antonio Uccelli, Jens Wuerfel

2021The Lancet Neurology109 citationsDOI

Topics & Concepts

MedicineTolerabilityClinical endpointMultiple sclerosisPlaceboExpanded Disability Status ScaleAdverse effectMesenchymal stem cellInternal medicineClinical trialOncologySurgeryPathologyImmunologyAlternative medicineMesenchymal stem cell researchNeurogenesis and neuroplasticity mechanismsMultiple Sclerosis Research Studies
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial | Litcius